Frontiers in Immunology · 2019 · 108 citations · 25 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor MicroenvironmentAntitumor T Cell ResponsesCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyCytokine BiologyImmunotherapy For Solid TumorsT Cell BiologyCytokine Targeted TherapyCytokine-mediated Immune ModulationCytokine-mediated T Cell ActivationCytokine-mediated T Cell ResponsesImmunosuppressive FunctionImmunosuppressive MicroenvironmentSolid Tumor Car T-cell TherapyStat3 Signaling
Incorporation of inverted cytokine receptor (ICR) such as interleukin (IL)-4 versus IL-7 (4/7) ICR is one strategy to improve the antitumor activities of chimeric antigen receptor (CAR) modified T (CAR-T) cells facing the immunosuppressive cytokines. Here we report a novel interleukin (IL)-4 versus IL-21 inverted cytokine receptor (4/21 ICR) that enhanced CAR-T cell potency in IL-4+ tumor milieu via a different working-mechanism from 4/7 ICR. Upon IL-4 stimulation, 4/21 ICR activated STAT3 pathway and promoted Th17-like polarization and tumor-targeted cytotoxicity in CAR-T cells in vitro. Furthermore, 4/21 ICR CAR T cells persisted and eradicated established IL-4+ tumors in vivo. Thus, 4/21 ICR would be promising to be clinically translated in CAR-T cell therapeutics for solid tumors rich in IL-4.
25
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner et al. · New England Journal of Medicine · 2018 · 5.6K citations · Full text
Medicine, Hematology, Oncology +17
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster, Jakub Svoboda, Elise A. Chong et al. · New England Journal of Medicine · 2017 · 1.9K citations · Full text
IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells
Thomas Korn, Estelle Bettelli, Wenda Gao et al. · Nature · 2007 · 1.8K citations